Comparison of the Long-term Efficacy and Safety of Gamma Knife Radiosurgery for Arteriovenous Malformations in Pediatric and Adult Patients

Hirotaka HASEGAWA,1 Shunya HANAKITA,1 Masahiro SHIN,1 Mariko KAWASHIMA,1 Wataru TAKAHASHI,2 Osamu ISHIKAWA,1 Satoshi KOIZUMI,1 Hirofumi NAKATOMI,1 and Nobuhito SAITO1

1Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan; 2Department of Radiology, University of Tokyo Hospital, Tokyo, Japan

Abstract

It is debated whether the efficacy and long-term safety of gamma knife radiosurgery (GKRS) for arteriovenous malformations (AVMs) differs between adult and pediatric patients. We aimed to clarify the long-term outcomes of GKRS in pediatric patients and how they compare to those in adult patients. We collected data for 736 consecutive patients with AVMs treated with GKRS between 1990 and 2014 and divided the patients into pediatric (age < 20 years, n = 144) and adult (age ≥ 20 years, n = 592) cohorts. The mean follow-up period in the pediatric cohort was 130 months. Compared to the adult patients, the pediatric patients were significantly more likely to have a history of hemorrhage (P < 0.001). The actuarial rates of post-GKRS nidus obliteration in the pediatric cohort were 36%, 60%, and 87% at 2, 3, and 6 years, respectively. Nidus obliteration occurred earlier in the pediatric cohort than in the adult cohort (P = 0.015). The actuarial rates of post-GKRS hemorrhage in the pediatric cohort were 0.7%, 2.5%, and 2.5% at 1, 5, and 10 years, respectively. Post-GKRS hemorrhage was marginally less common in the pediatric cohort than in the adult cohort (P = 0.056). Cyst formation/encapsulated hematoma were detected in seven pediatric patients (4.9%) at a median post-GKRS timepoint of 111 months, which was not significantly different from the rate in the adult cohort. Compared to adult patients, pediatric patients experience earlier therapeutic effects from GKRS for AVMs, and this improves long-term outcomes.

Key words: arteriovenous malformation, gamma knife, pediatric patients, stereotactic radiosurgery

Introduction

Most arteriovenous malformations (AVMs) became symptomatic when patients are 30–40 years old,1–4 but AVMs are also an important cause of hemorrhagic stroke in younger patients, accounting for approximately half of spontaneous intracranial hemorrhagic strokes in patients younger than 18 years.5 Previous reports have suggested that the characteristics and biological behaviors of AVMs differ somewhat between pediatric and adult patients. Briefly, pediatric patients reportedly have stronger hemorrhage tendencies and smaller nidus sizes, are more likely to exhibit deep locations and deep venous drainage, and are less likely to exhibit dangerous angioarchitectural features, such as venous ectasia and feeding artery aneurysms.6–9

Gamma knife radiosurgery (GKRS) is a standard AVM treatment and generally provides a 70–85% obliteration rate after 3–5 years and a low morbidity rate.10–38 Some researchers insist that AVMs in pediatric patients are especially sensitive to radiation, which increases the chances of nidus obliteration,10,14,39–41 though not all studies have observed this trend.20,42–46 However, improved understanding of late radiation-induced complications47–64 has illuminated the need to clarify the long-term safety of GKRS, especially in pediatric patients who have much longer residual life expectancies than adult patients do. Given these concerns, we aimed to determine how the long-term outcomes of GKRS for AVMs in pediatric patients compared to those in adult patients.

Materials and Methods

Participants

We collected clinical and radiographic data for consecutive patients who were treated with GKRS
between 1990 and 2014 and divided the patients into pediatric (age < 20 years) and adult (age ≥ 20 years) cohorts. After we excluded patients who (i) underwent staged GKRS (n = 21) or (ii) other radiotherapies (n = 13) before the first GKRS in our institution, (iii) received suboptimal (<15 Gy) treatment (n = 4), or (iv) received no follow-up care (n = 17), 736 patients remained. This sample included 144 pediatric patients (mean follow-up period: 130 months; median follow-up period: 105 months; range: 5–316 months) and 592 adult patients (mean follow-up period: 110 months; median follow-up period: 92 months; range: 1–320 months). The study protocol was approved by our institutional review board and conformed to the principles of the Declaration of Helsinki. All patients provided written informed consent for the use of their data.

Radiosurgical techniques
Details of our hospital’s radiosurgical techniques have been previously described. In brief, a Leksell stereotactic frame (Elekta Instruments, Stockholm, Sweden) was fixed on the patient’s head, and stereotactic imaging was then performed to obtain precise data on the shape, volume, and three-dimensional coordinates of the patient’s head. Digital subtraction angiography (DSA) was used before February 1991, computed tomography was used from March 1991 to July 1996, and magnetic resonance imaging (MRI) was used from August 1996 onward. Treatments were planned by dedicated neurosurgeons and radiation oncologists using KULA software until 1998 and the Leksell Gamma Plan thereafter (both software packages are from Elekta Instruments). Radiosurgical dose determinations were mainly based on nidus sizes and proximity to eloquent structures, and the prescribed doses mostly ranged between 18 and 20 Gy. We performed all procedures without general anesthesia. Instead, intravenous sedative agents (i.e., midazolam, thiopental, and/or pentazocine) were used before frame fixation, with support from pediatricians for patients younger than 13–15 years. The procedure was performed with the patient either fully conscious or under sedation, as considered appropriate.

Post-treatment course
Patients were evaluated at regular intervals after GKRS. MRI scans were performed at 6-month intervals for the first 3 years, with confirmatory DSA being performed if the MRI results suggested nidus obliteration. Secondary GKRS was recommended for patients who did not exhibit nidus obliteration within approximately 5 years. Annual MRI check-ups were continued after nidus obliteration to screen for possible long-term complications. We defined event-free survival (EFS) as survival free from any permanent symptomatic complications that were caused by AVMs themselves or AVM treatments (including surgery, embolization, and radiotherapy) and that were associated with a >1-point deterioration in the patient’s modified Rankin Scale (mRS) score relative to baseline. We also searched for late cyst formation and/or encapsulated hematoma (CF/EH), which was typically characterized by a radiographically-evident enhanced nodular lesion with or without cyst formation with perifocal edema.

Statistical analyses
The examined baseline characteristics included age, biological sex, maximal nidus diameter, nidus volume, radiosurgical dose, depth of location, presence of a deep drainer, eloquent location, history of hemorrhage, surgery, and embolization, the Modified Pittsburgh Radiosurgery-based AVM Grading Scale, the Spetzler–Martin Grade, and the Virginia radiosurgical AVM Grading Scale. Baseline characteristics between the two cohorts were compared using the chi-square test for categorical variables and the Wilcoxon rank sum test for continuous variables. We calculated the actuarial rates of nidus obliteration, post-GKRS hemorrhage, and perifocal edema and the EFS rate with the Kaplan–Meier method and compared the cohorts’ curves with the Wilcoxon test. All analyses were performed with JMP Pro 13 software (SAS Institute, Cary, NC, USA). We defined statistical significance as P < 0.05.

Results
Baseline characteristics
The patients’ baseline characteristics are summarized in Table 1. The median ages were 14.5 years (range: 4–19 years) and 38 years (range: 20–80 years) in the pediatric and adult cohort, respectively. Histories of AVM embolization and hemorrhage were present in 24 (17%) and 102 (71%) pediatric patients, respectively, and 63 (11%) and 311 (53%) adult patients, respectively. Compared to the adult patients, the pediatric patients were significantly more likely to have a history of hemorrhage (P < 0.001) or a history of prior embolization (P = 0.045). The statistical analysis also revealed the margin dose in pediatric patients which was significantly higher than in adult patients (P = 0.020), but the difference was so slight and the median values were the same that no virtual difference was present. There were no observed complications associated with sedation, frame fixation, or GKRS itself.
Nidus obliteration

Nidus obliteration was confirmed in 105 pediatric patients (73%) at a median timepoint of 24 months after initial GKRS. The actuarial obliteration rates were 36, 60, 74, and 87% at 2–4, and 6 years, respectively. Secondary GKRS was performed in 16 pediatric patients, with subsequent nidus obliteration confirmed in nine patients. In total, nidus obliteration was confirmed in 114 pediatric patients (79%). Nidus obliteration was confirmed in 391 adult patients (66%) at a median timepoint of 30 months after initial GKRS. The actuarial obliteration rates were 23, 53, 73, and 85% at 2–4, and 6 years, respectively. A Kaplan–Meier analysis revealed that nidus obliteration occurred significantly earlier in the pediatric cohort \( (P = 0.015, \text{Fig. 1A}) \).

Post-GKRS hemorrhage

Post-GKRS hemorrhage was observed in five pediatric patients (4.0%) at a median timepoint of 59 months after GKRS. All were from unobliterated niduses, except for in one patient who developed a hemorrhage from a recurrent nidus 240 months after the initial GKRS. The actuarial post-GKRS hemorrhage rates were 0.7, 0.7, 2.5, and 2.5% at 1, 2, 5, and 10 years, respectively. Post-GKRS hemorrhage was observed in 38 adult patients (6.4%) at a median timepoint of 13 months after GKRS. The actuarial post-GKRS hemorrhage rates were 2.9, 4.9, 5.5, and 6.4% at 1, 2, 5, and 10 years, respectively. A Kaplan–Meier analysis revealed a tendency toward a lower post-GKRS hemorrhage frequency in the pediatric cohort \( (P = 0.056, \text{Fig. 1B}) \).

Perifocal edema

Post-GKRS perifocal edema was observed in 41 pediatric patients (28%) at a median timepoint of 11 months. The actuarial perifocal edema rates were 23, 30, and 30% at 1–3 years, respectively, which were not significantly different from the adult cohort’s actuarial rates of 15, 30, and 32% at 1–3 years, respectively \( (P = 0.560, \text{Fig. 1C}) \).

EFS

Neurological deteriorations (i.e., >1-point mRS score decreases) were observed in four pediatric patients (2.8%). Two of them with niduses located in the thalamus and internal capsule experienced incomplete right hemiparesis 11 months after GKRS, and one of these patients later developed a fatal encapsulated hematoma, as previously reported.\(^{47}\) A third patient died due to massive cerebellar hemorrhage at 6 years, and the fourth patient developed diplopia due to an encapsulated hematoma at 75 months, which required surgical resection. The overall pediatric EFS rates were 99, 98, 96, and 96% at 2, 5, 10, and 15 years, respectively \( (P = 0.349, \text{Fig. 1D}) \).

CF/EH

Cyst formation and/or encapsulated hematoma was detected in seven pediatric patients (4.9%) at...
a median timepoint of 111 months (range: 23–243 months) after initial GKRS. These caused mild deficits or no clinical outcomes in six patients but killed the remaining one patient. No radiation-induced tumor was observed in the pediatric patients. On the other hand, CF/EH were detected in 35 adult patients (5.9%) at a median timepoint of 135 months after initial GKRS. No significance between-cohort differences were observed in the CF/EH incidence rates ($P = 0.626$) or the post-GKRS timepoint of CF/EH development ($P = 0.532$).

**Discussion**

In this study, we compared the outcomes of GKRS for AVMs in pediatric and adult cohorts. Our first major finding was that although the two cohorts’ final obliteration rates were almost equal, nidus obliteration occurred earlier in the pediatric cohort than in the adult cohort. Second, post-GKRS hemorrhage occurred less frequently and later in the pediatric cohort than in the adult cohort. These results are especially impressive given that the pediatric cohort had a significantly higher proportion of hemorrhagic AVMs than the adult cohort did, and that previous hemorrhages are a major risk factor for post-GKRS hemorrhage.\(^4,8,71–73\) It can obviously be speculated that shorter times to nidus obliteration in the pediatric cohort could have contributed to a reduced frequency of latency-phase hemorrhage. Several previous studies have also confirmed earlier response to radiation in pediatric patients than in adult patients.\(^10,14,39–41\) One possible explanation for this is that vessels in adult and pediatric patients may differ in sensitivity to radiation-induced damage.\(^16\) For example, AVMs in pediatric patients may have a higher endothelial cell turnover rate in the nidus than AVMs in adults do. The major pieces of evidence for this hypothesis are that AVM recurrence both after radiotherapy and surgery is more commonly observed in young patients\(^74–79\) and that AVM-affected vessels in pediatric patients tend to have a high Ki-67 index and high vascular endothelial growth factor expression.\(^80,81\) Interestingly, some previous studies reported that...
elderly and non-elderly populations differ in the rate\textsuperscript{70} and timing\textsuperscript{82} of nidus obliteration, which suggests that radiation sensitivity may depend on age. Further research is necessary.

In this study, we did not observe any complications associated with treatment procedures such as frame fixation; stereotactic imaging studies, including angiography; or irradiation. Nevertheless, meticulous care should be taken to maintain an ideal sedative state, especially in younger children, and effective collaboration with pediatricians is essential. We performed all procedures with the patients under local anesthesia with sedative agents, but the need of general anesthesia should be argued individually.

Cyst formation and/or encapsulated hematoma are rare but possible late radiation-induced complications following GKRS for AVMs.\textsuperscript{51,52,57,60,83–85} We observed a CF/EH incidence rate of approximately 5% in both the pediatric and adult cohorts. Although fatal outcomes are possible if CF/EH develops in deep brain regions, most CF/EHs developed slowly and caused only mild deficits or even no adverse outcomes. We therefore recommend annual regular imaging follow-up for all treated patients. It remains controversial when follow-up should cease. Because we found that some CF/EHs developed more than 20 years after the initial GKRS, we suggest that follow-up should continue for at least 20 years, but we should conduct further research to stratify the CF/EH risk in different patients and examine whether the follow-up period can be safely shortened.

This study has some limitations. First, its retrospective nature might have introduced selection biases in terms of participants and treatments. Nevertheless, our results are consistent with those of recent studies of pediatric patients,\textsuperscript{19,25,86–92} which suggests that they are robust and applicable to clinical practice. Second, there was a sample size imbalance between the pediatric and adult cohorts. Sample size uniformity between cohorts is ideal for statistical comparisons, but it is usually an unattainable goal for clinical studies. Hence, we conducted this study in the best available way. Third, we defined EFS as any neurological event that caused a >1-point decrease in mRS scores, which in turn means that subtle complications or controllable epilepsies were not counted. However, because many surgical cohort studies define significant complications as events causing >1 to 2-point decreases in mRS scores or their equivalent,\textsuperscript{93–98} our EFS definition is acceptable.

Overall, GKRS for AVMs in pediatric patients can provide a favorable nidus obliteration rate within a shorter timeframe than achieved in adult patients. It also provides a favorable EFS even ≥10 years after treatment. Therefore, GKRS is an optimal treatment for pediatric AVMs. However, additional studies are necessary to further evaluate long-term outcomes, because pediatric patients have long residual life expectancies.

**Conflicts of Interest Disclosure**

All authors have no conflict of interest.

**References**

1) Graf CJ, Perret GE, Torner JC: Bleeding from cerebral arteriovenous malformations as part of their natural history. *J Neurosurg* 58: 331–337, 1983

2) Ondra SL, Troupp H, George ED, Schwab K: The natural history of symptomatic arteriovenous malformations of the brain: A 24-year follow-up assessment. *J Neurosurg* 73: 387–391, 1990

3) Marks MP, Lane B, Steinberg GK, Chang PJ: Hemorrhage in intracerebral arteriovenous malformations: angiographic determinants. *Radiology* 176: 807–813, 1990

4) Gross BA, Du R: Natural history of cerebral arteriovenous malformations: a meta-analysis. *J Neurosurg* 118: 437–443, 2013

5) Meyer-Heim AD, Bolotshauser E: Spontaneous intracranial haemorrhage in children: aetiology, presentation and outcome. *Brain Dev* 25: 416–421, 2003

6) Hetts SW, Cooke DL, Nelson J, et al.: Influence of patient age on angioarchitecture of brain arteriovenous malformations. *AJNR Am J Neuroradiol* 35: 1376–1380, 2014

7) Ellis MJ, Armstrong D, Vachhrajani S, et al.: Angioarchitectural features associated with hemorrhagic presentation in pediatric cerebral arteriovenous malformations. *J Neurointerv Surg* 5: 191–195, 2013

8) Stapf C, Mast H, Sciaccia RR, et al.: Predictors of hemorrhage in patients with untreated brain arteriovenous malformation. *Neurology* 66: 1350–1355, 2006

9) Fullerton HJ, Achrol AS, Johnston SC, et al.: Long-term hemorrhage risk in children versus adults with brain arteriovenous malformations. *Stroke* 36: 2099–2104, 2005

10) Pollock BE, Flickinger JC, Lunsford LD, Maitz A, Kondziolka D: Factors associated with successful arteriovenous malformation radiosurgery. *Neurosurgery* 42: 1239–1244; discussion 1244–1247, 1998

11) Pan DH, Guo WY, Chung WY, Shiu CY, Chang YC, Wang LW: Gamma knife radiosurgery as a single treatment modality for large cerebral arteriovenous malformations. *J Neurosurg* 93 Suppl 3: 113–119, 2000
12) Pollock BE, Flickinger JC: A proposed radiosurgery-based grading system for arteriovenous malformations. J Neurosurg 96: 79–85, 2002
13) Flickinger JC, Kondziolka D, Maitz AH, Lunsford LD: An analysis of the dose-response for arteriovenous malformation radiosurgery and other factors affecting obliteration. Radiother Oncol 63: 347–354, 2002
14) Shin M, Kawamoto S, Kurita H, et al.: Retrospective analysis of a 10-year experience of stereotactic radio surgery for arteriovenous malformations in children and adolescents. J Neurosurg 97: 779–784, 2002
15) Liscak R, Vladyka V, Simonová G, et al.: Arteriovenous malformations after Leksell gamma knife radiosurgery: rate of obliteration and complications. Neurosurgery 60: 1005–1014; discussion 1015–1016, 2007
16) Pan DH, Kuo YH, Guo WY, et al.: Gamma Knife surgery for cerebral arteriovenous malformations in children: A 13-year experience. J Neurosurg Pediatr 1: 296–304, 2008
17) Kano H, Lunsford LD, Flickinger JC, et al.: Stereotactic radiosurgery for arteriovenous malformations, part 1: management of spetzler-martin grade I and II arteriovenous malformations. J Neurosurg 116: 11–20, 2012
18) Kano H, Kondziolka D, Flickinger JC, et al.: Stereotactic radiosurgery for arteriovenous malformations, part 3: outcome predictors and risks after repeat radiosurgery. J Neurosurg 116: 21–32, 2012
19) Kano H, Kondziolka D, Flickinger JC, et al.: Stereotactic radiosurgery for arteriovenous malformations, part 2: management of pediatric patients. J Neurosurg Pediatr 9: 1–10, 2012
20) Fokas E, Henzel M, Wittig A, Grund S, Engenhart-Cabillic R: Stereotactic radiosurgery of cerebral arteriovenous malformations: long-term follow-up in 164 patients of a single institution. J Neurol 260: 2156–2162, 2013
21) Kano H, Flickinger JC, Yang HC, et al.: Stereotactic radiosurgery for spetzler-martin grade III arteriovenous malformations. J Neurosurg 120: 973–981, 2014
22) Hanakita S, Koga T, Shin M, Igaki H, Saito N: Application of single-stage stereotactic radiosurgery for cerebral arteriovenous malformations >10 cm³. Stroke 45: 3543–3548, 2014
23) Ding D, Starke RM, Yen CP, Sheehan JP: Radiosurgery for cerebellar arteriovenous malformations: does infratentorial location affect outcome? World Neurosurg 82: e209–e217, 2014
24) Ding D, Xu Z, Yen CP, Starke RM, Sheehan JP: Radiosurgery for cerebral arteriovenous malformations in elderly patients: Effect of advanced age on outcomes after intervention. World Neurosurg 84: 795–804, 2015
25) Nicolato A, Longhi M, Tommasi N, et al.: Leksell Gamma Knife for pediatric and adolescent cerebral arteriovenous malformations: results of 100 cases followed up for at least 36 months. J Neurosurg Pediatr 16: 736–747, 2015
26) Hanakita S, Koga T, Shin M, Igaki H, Saito N: The long-term outcomes of radiosurgery for arteriovenous malformations in pediatric and adolescent populations. J Neurosurg Pediatr 16: 222–231, 2015
27) Maruyama K, Kawahara N, Shin M, et al.: The risk of hemorrhage after radiosurgery for cerebral arteriovenous malformations. N Engl J Med 352: 146–153, 2005
28) Friedman WA, Blatt DL, Bova FJ, Buatti JM, Mendenhall WM, Kubilis PS: The risk of hemorrhage after radiosurgery for arteriovenous malformations. J Neurosurg 84: 912–919, 1996
29) Pollock BE, Flickinger JC, Lunsford LD, Bissonette DJ, Kondziolka D: Hemorrhage risk after stereotactic radiosurgery of cerebral arteriovenous malformations. Neurosurgery 38: 652–659; discussion 659–661, 1996
30) Karlsson B, Lax I, Söderman M: Risk for hemorrhage during the 2-year latency period following Gamma Knife radiosurgery for arteriovenous malformations. Int J Radiat Oncol Biol Phys 49: 1045–1051, 2001
31) Ganz JC, Reda WA, Abdelkarim K: Adverse radiation effects after Gamma Knife surgery in relation to dose and volume. Acta Neurochir (Wien) 151: 9–19, 2009
32) Bollet MA, Anxionnat R, Buchheit I, et al.: Efficacy and morbidity of arc-therapy radiosurgery for cerebral arteriovenous malformations: a comparison with the natural history. Int J Radiat Oncol Biol Phys 58: 1353–1363, 2004
33) Flickinger JC, Lunsford LD, Kondziolka D, et al.: Radiosurgery and brain tolerance: An analysis of neurodiagnostic imaging changes after Gamma Knife radiosurgery for arteriovenous malformations. Int J Radiat Oncol Biol Phys 23: 19–26, 1992
34) Flickinger JC, Kondziolka D, Maitz AH, Lunsford LD: Analysis of neurological sequelae from radiosurgery of arteriovenous malformations: how location affects outcome. Int J Radiat Oncol Biol Phys 40: 273–278, 1998
35) Flickinger JC, Kondziolka D, Lunsford LD, et al.: A multi-institutional analysis of complication outcomes after arteriovenous malformation radiosurgery. Int J Radiat Oncol Biol Phys 44: 67–74, 1999
36) Flickinger JC, Kondziolka D, Lunsford LD, et al.: Development of a model to predict permanent symptomatic postradiosurgery injury for arteriovenous malformation patients. Arteriovenous malformation radiosurgery study group. Int J Radiat Oncol Biol Phys 46: 1143–1148, 2000
37) Cohen-Inbar O, Lee CC, Xu Z, Schlesinger D, Sheehan JP: A quantitative analysis of adverse radiation effects following Gamma Knife radiosurgery for arteriovenous malformations. J Neurosurg 123: 945–953, 2015
38) Yen CP, Matsumoto JA, Wintermark M, et al.: Radiation-induced imaging changes following Gamma Knife surgery for cerebral arteriovenous malformations. J Neurosurg 118: 63–73, 2013
39) Tanaka T, Kobayashi T, Kida Y, Oyama H, Niwa M: Comparison between adult and pediatric arteriovenous malformations treated by Gamma Knife.
radiosurgery. *Stereotact Funct Neurosurg* 66 Suppl 1: 288–295, 1996
40) Nicolato A, Lupidi F, Sandri MF, et al.: Gamma Knife radiosurgery for cerebral arteriovenous malformations in children/adolescents and adults. Part II: Differences in obliteration rates, treatment-obliteration intervals, and prognostic factors. *Int J Radiat Oncol Biol Phys* 64: 914–921, 2006
41) Reins N, Blond S, Gauvrit JY, et al.: Role of radiosurgery in the management of cerebral arteriovenous malformations in the pediatric age group: data from a 100-patient series. *Neurosurgery* 60: 268–276; discussion 276, 2007
42) Yen CP, Monteith SJ, Nguyen JH, Rainey J, Schlesinger DJ, Sheehan JP: Gamma Knife surgery for arteriovenous malformations in children. *J Neurosurg Pediatr* 6: 426–434, 2010
43) Maruyama K, Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD: Stereotactic radiosurgery for brain-stem arteriovenous malformations: factors affecting outcome. *J Neurosurg* 100: 407–413, 2004
44) Potts MB, Jahangiri A, Jen M, et al.: Deep arteriovenous malformations in the basal ganglia, thalamus, and insula: multimodality management, patient selection, and results. *World Neurosurg* 82: 386–394, 2014
45) Boström JP, Bruckermann R, Pintea B, Boström A, Surber G, Hamm K: Treatment of cerebral arteriovenous malformations with radiosurgery or hypofractionated stereotactic radiotherapy in a consecutive pooled linear accelerator series. *World Neurosurg* 94: 328–338, 2016
46) Knippen S, Putz F, Semrau S, et al.: Predictors for occlusion of cerebral AVMs following radiation therapy: Radiation dose and prior embolization, but not spetzler-martin grade. *Strahlenther Onkol* 193: 185–191, 2017
47) Kurita H, Sasaki T, Kawamoto S, et al.: Chronic encapsulated expanding hematoma in association with Gamma Knife stereotactic radiosurgery for a cerebral arteriovenous malformation. Case report. *J Neurosurg* 84: 874–878, 1996
48) Schaller C, Liefner M, Ansari S, Al Moutaery K: Operation for delayed symptomatic brain oedema after treatment of an arteriovenous malformation by embolization and radiosurgery. *Acta Neurochir* (Wien) 147: 1103–1108; discussion 1108, 2005
49) Lee CC, Pan DH, Ho DM, et al.: Chronic encapsulated expanding hematoma after Gamma Knife stereotactic radiosurgery for cerebral arteriovenous malformation. *Clin Neurol Neurosurg* 113: 668–671, 2011
50) Takeuchi S, Takasato Y, Masaoka H: Chronic encapsulated intracerebral hematoma formation after radiosurgery for cerebral arteriovenous malformation. *Neurol India* 59: 624–626, 2011
51) Shuto T, Yagishita S, Matsunaga S: Pathological characteristics of cyst formation following Gamma Knife surgery for arteriovenous malformation. *Acta Neurochir* (Wien) 157: 293–298, 2015
52) Malikova H, Koubeka E, Vojtech Z, et al.: Late morphological changes after radiosurgery of brain arteriovenous malformations: an MRI study. *Acta Neurochir* (Wien) 158: 1683–1690, 2016
53) Ilyas A, Chen CJ, Ding D, et al.: Cyst formation after stereotactic radiosurgery for brain arteriovenous malformations: a systematic review. *J Neurosurg* 128: 1354–1363, 2018
54) Kihlström L, Guo WY, Karlsson B, Lindquist C, Lindqvist M: Magnetic resonance imaging of obliterated arteriovenous malformations up to 23 years after radiosurgery. *J Neurosurg* 86: 589–593, 1997
55) Radanowicz-Hartmann V, Bächli H, Gratzl O: Late complication of radiosurgery of AVMs with the gamma knife: a case report. *Acta Neurochir* (Wien) 140: 194–195, 1998
56) Yamamoto M, Hara M, Ide M, Ono Y, Jimbo M, Saito I: Radiation-related adverse effects observed on neuro-imaging several years after radiosurgery for cerebral arteriovenous malformations. *Surg Neurol* 49: 385–397; discussion 397–398, 1998
57) Matsu T, Kamada K, Izumo T, Hayashi N, Nagata I: Cyst formation after linac-based radiosurgery for arteriovenous malformation: examination of predictive factors using magnetic resonance imaging. *Clin Neurosurg Neurosurg 121*: 10–16, 2014
58) Nakamizo A, Suzuki SO, Saito N, et al.: Clinicopathological study on chronic encapsulated expanding hematoma associated with incompletely obliterated AVM after stereotactic radiosurgery. *Acta Neurochir* (Wien) 153: 883–893, 2011
59) Watanabe T, Nagamine H, Ishiuchi S: Progression of cerebellar chronic encapsulated expanding hematoma during late pregnancy after Gamma Knife radiosurgery for arteriovenous malformation. *Surg Neurol Int* 5: S575–S579, 2014
60) Shuto T, Matsunaga S, Suenaga J: Surgical treatment for late complications following Gamma Knife surgery for arteriovenous malformations. *Stereotact Funct Neurosurg* 89: 96–102, 2011
61) Kaido T, Hoshida T, Uranishi R, et al.: Radiosurgery-induced brain tumor. Case report. *J Neurosurg* 95: 710–713, 2001
62) Yoshida K, Ichikawa T, Kurozumi K, Yanai H, Onoda K, Date I: Fatal glioblastoma after Gamma Knife radiosurgery for arteriovenous malformation in a child. *J Clin Neurosci* 21: 1453–1455, 2014
63) Berman EL, Eade TN, Brown D, et al.: Radiation-induced tumor after stereotactic radiosurgery for an arteriovenous malformation: case report. *Neurosurgery* 61: E1099; discussion E1099, 2007
64) Xhumari A, Rroji A, Enesi E, Bushati T, Sallabanda Diaz K, Petrela M: Glioblastoma after AVM radiosurgery. Case report and review of the literature. *Acta Neurochir* (Wien) 157: 889–895, 2015
65) Koga T, Shin M, Saito N: Treatment with high marginal dose is mandatory to achieve long-term control of skull base chordomas and chondrosarcomas
by means of stereotactic radiosurgery. J Neurooncol 98: 233–238, 2010

66) Shin M, Kawahara N, Maruyama K, Tago M, Ueki K, Kirino T: Risk of hemorrhage from an arteriovenous malformation confirmed to have been obliterated on angiography after stereotactic radiosurgery. J Neurosurg 102: 842–846, 2005

67) van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19: 604–607, 1988

68) Wegner RE, Oysul K, Pollock BE, et al.: A modified radiosurgery-based arteriovenous malformation grading scale and its correlation with outcomes. Int J Radiat Oncol Biol Phys 79: 1147–1150, 2011

69) Spetzler RF, Martin NA: A proposed grading system for arteriovenous malformations. J Neurosurg 65: 476–483, 1986

70) Starke RM, Yen CP, Ding D, Sheehan JP: A practical grading scale for predicting outcome after radiosurgery for arteriovenous malformations: analysis of 1012 treated patients. J Neurosurg 119: 981–987, 2013

71) Ding D, Yen CP, Starke RM, Xu Z, Sheehan JP: Effect of prior hemorrhage on intracranial arteriovenous malformation radiosurgery outcomes. Cerebrovasc Dis 39: 53–62, 2015

72) Gross BA, Du R: Rate of re-bleeding of arteriovenous malformations in the first year after rupture. J Clin Neurosci 19: 1087–1088, 2012

73) Pollock BE, Flickinger JC, Lunsford LD, Bissonette DJ, Kondziolka D: Factors that predict the bleeding risk of cerebral arteriovenous malformations. Stroke 27: 1–6, 1996

74) Morgenstern PF, Hoffman CE, Kocharian G, Singh R, Stieg PE, Souweidane MM: Postoperative imaging for detection of recurrent arteriovenous malformations in children. J Neurosurg Pediatr 17: 134–140, 2016

75) Ali MJ, Bendok BR, Rosenblatt S, Rose JE, Getch CC, Batjer HH: Recurrence of pediatric cerebral arteriovenous malformations after angiographically documented resection. Pediatr Neurosurg 39: 32–38, 2003

76) Andaluz N, Mysore JS, Sathi S, Crone KR, Tew JM: Recurrence of cerebral arteriovenous malformations in children: report of two cases and review of the literature. Surg Neurol 62: 324–330; discussion 330–331, 2004

77) Lang SS, Beslow LA, Bailey RL, et al.: Follow-up imaging to detect recurrence of surgically treated pediatric arteriovenous malformations. J Neurosurg Pediatr 9: 497–504, 2012

78) Yun JH, Kwon DH, Lee EJ, Lee DH, Ahn JS, Kwun BD: New nidus formation adjacent to the target site of an arteriovenous malformation treated by Gamma Knife surgery. J Neurosurg 117 Suppl: 120–125, 2012

79) Hashimoto N, Nozaki K: Do cerebral arteriovenous malformations recur after angiographically confirmed total extirpation? Crit Rev Neurosurg 9: 141–146, 1999

80) Sonstein WJ, Kader A, Michelsen WJ, Llena JF, Hirano A, Casper D: Expression of vascular endothelial growth factor in pediatric and adult cerebral arteriovenous malformations: an immunocytochemical study. J Neurosurg 85: 838–845, 1996

81) Hashimoto T, Mesa-Tejada R, Quick CM, et al.: Evidence of increased endothelial cell turnover in brain arteriovenous malformations. Neurosurgery 49: 124–131; discussion 131–132, 2001

82) Hasegawa H, Hanakita S, Shin M, et al.: Does advanced age affect the outcomes of stereotactic radiosurgery for cerebral arteriovenous malformation? World Neurosurg 109: e715–e723, 2018

83) Pollock BE, Link MJ, Branda ME, Storlie CB: Incidence and management of late adverse radiation effects after arteriovenous malformation radiosurgery. Neurosurgery 61: 928–934, 2017

84) Izawa M, Hayashi M, Chernov M, et al.: Long-term complications after gamma knife surgery for arteriovenous malformations. J Neurosurg 102 Suppl: 34–37, 2005

85) Pan HC, Sheehan J, Stroila M, Steiner M, Steiner L: Late cyst formation following gamma knife surgery of arteriovenous malformations. J Neurosurg 102: 124–127, 2005

86) Nicolato A, Foroni R, Seghedoni A, et al.: Leksell gamma knife radiosurgery for cerebral arteriovenous malformations in pediatric patients. Childs Nerv Syst 21: 301–307; discussion 308, 2005

87) Galván De la Cruz OO, Ballesteros-Zebadúa P, Moreno-Jímenez S, Celis MA, García-Garduño OA: Stereotactic radiosurgery for pediatric patients with intracranial arteriovenous malformations: variables that may affect obliteration time and probability. Clin Neurol Neurosurg 129: 62–66, 2015

88) Ding D, Xu Z, Yen CP, Starke RM, Sheehan JP: Radiosurgery for unruptured cerebral arteriovenous malformations in pediatric patients. Acta Neurochir (Wien) 157: 281–291, 2015

89) Smyth MD, Sneed PK, Ciricillo SF, et al.: Stereotactic radiosurgery for pediatric intracranial arteriovenous malformations: the University of California at San Francisco experience. J Neurosurg 97: 48–55, 2002

90) Buis DR, Dirven CM, Lagerwaard FJ, et al.: Radiosurgery of brain arteriovenous malformations in children. J Neuro 255: 551–560, 2008

91) Potts MB, Sheth SA, Louie J, et al.: Stereotactic radiosurgery at a low marginal dose for the treatment of pediatric arteriovenous malformations: obliteration, complications, and functional outcomes. J Neurosurg Pediatr 14: 1–11, 2014

92) Kondziolka D, Kano H, Yang HC, Flickinger JC, Lunsford L: Radiosurgical management of pediatric arteriovenous malformations. Childs Nerv Syst 26: 1359–1366, 2010

93) Schramm J, Schaller K, Esche J, Boström A: Microsurgery for cerebral arteriovenous malformations: subgroup outcomes in a consecutive series of 288 cases. J Neurosurg 126: 1056–1063, 2017

94) Korja M, Bervini D, Assaad N, Morgan MK: Role of surgery in the management of brain arteriovenous malformations.

Neurol Med Chir (Tokyo) 58, June, 2018
malformations: prospective cohort study. *Stroke* 45: 3549–3555, 2014

95) Hartmann A, Stapf C, Hofmeister C, et al.: Determinants of neurological outcome after surgery for brain arteriovenous malformation. *Stroke* 31: 2361–2364, 2000

96) Lawton MT; UCSF Brain Arteriovenous Malformation Study Project: Spetzler-martin grade III arteriovenous malformations: surgical results and a modification of the grading scale. *Neurosurgery* 52: 740–748; discussion 748–749, 2003

97) Schaller C, Schramm J, Haun D: Significance of factors contributing to surgical complications and to late outcome after elective surgery of cerebral arteriovenous malformations. *J Neurol Neurosurg Psychiatry* 65: 547–554, 1998

98) Pik JH, Morgan MK: Microsurgery for small arteriovenous malformations of the brain: results in 110 consecutive patients. *Neurosurgery* 47: 571–575; discussion 575–577, 2000

Address reprint requests to: Hirotaka Hasegawa, MD, Department of Neurosurgery, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

e-mail: hirohasegawa-tsky@umin.ac.jp